Navigation Links
Forever young: Differentiation blocked in tumor stem cells
Date:1/7/2008

A new comparison of normal stem cells and cancer stem cells reveals that the cancer stem cells are abnormally trapped at an early stage of development. The research, published by Cell Press in the January issue of Cancer Cell, significantly advances the understanding of glioma pathophysiology and provides new directions for design of therapeutic strategies that are targeted to specific types of tumors.

Tumor-initiating cells with stem like properties (TICs) are thought to be a small population of tumor cells that have many characteristics in common with normal stem cells (NSCs) in that they are self-replicating and capable of giving rise to populations of differentiated cells. Previous research has demonstrated that TICs are present in different types of brain tumors, including glioblastomas. Although the TICs share many properties with NSCs, they are known to possess genetic aberrations that support a tumorigenic phenotype.

Thus far, there have been few, if any, reports demonstrating exactly where along the developmental pathway of tissue-specific stem cell maturation and differentiation tumor stem cells arise, and which, if any, of the intrinsic stem cell signaling pathways are perturbed in tumor stem cells remains largely unknown, explains Dr. Howard A. Fine from the National Cancer Institute in Bethesda, Maryland. To better understand the development and differentiation pathways that play a significant role in cancer stem cells, Dr. Fine and colleagues isolated TICs from primary human glioblastomas and compared them to human and mouse NSCs at various developmental stages.

The researchers found that the TICs isolated from an adult patient are more similar to early embryonic stem cells than to later embryonic or adult-derived stem cells. Specifically, the TICs appear to be stuck at this early developmental stage, at least in part, due to epigenetic repression of bone morphogenic protein receptor 1B (BMPR1B) expression mediated
'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure
2. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
3. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
4. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
5. Study details regulation of vital tumor suppressor gene p53
6. Human C-reactive protein regulates myeloma tumor cell growth and survival
7. Customized virus kills brain tumor stem cells that drive lethal cancer
8. Study suggests brain tumors need treatment with multiple targeted drugs
9. Bright tumors, dim prospects
10. National Brain Tumor Foundation Unites with BrainLAB in Support of Patient Education
11. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...p://www.aronowitzmd.com [Los Angeles cosmetic sur...e in plastic surgery procedures for post bariatric...be necessary for these patients, health and wellne...pecialty of procedures for after weight loss. , ...ust 29, 2008 -- Bariatric surgery improves the hea...
(Date:8/28/2008)...onventional therapy, study found , , THU...a treadmill improves brain function and fitness fo...gh the usual rehabilitation program, a new study f...s have," said study researcher Dr. Andreas Luft, a...tation at the University of Zurich in Switzerland....
(Date:8/28/2008)...l efforts of the Maryland Medicaid contract, HARR...onal medical,management firm, appointed Lenaye Law...r. Dr. Lawyer will oversee all clinical aspects of...nt Valley, Maryland Harrisburg,office., "Dr. Lawy...land," said,Alice Stollenwerk Petrulis, MD, FACP, ...
(Date:8/28/2008)... physical, especially for the impaired, study says...-- A new study says that 13 percent of American se...use. , The University of Chicago researchers s... being taken advantage of financially (3.5 percent... found that seniors with physical impairments were...
Breaking Medicine News(10 mins):Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:Treadmill Workouts Help Stroke Survivors 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:13% of Seniors Report Being Mistreated 2
...sandro Remo Zanetti and his colleagues from Instit...ination with Hepatitis B produces the required con... of the patients for long periods//. The researche...inst Hepatitis B vaccination are present in the bl...
... infections are a major cause for hospitalization ...ection are risks for subsequent amputation. Ischem...betes combine to produce tissue necrosis and ulcer...lly polymicrobial in nature. Early recognition of ...
...morphins are highly powerful a tool for pain manag...rived from the opium poppy. It has previously been...erns// of side effects by virtue of their hard-wir...ceptors. Such receptors, known as u-opioids, appea...
... study conducted on factors that predispose to dri...’s tendency to do things like lie, steal or skip s...at a very early age of 12, 13 or 14//. The study ...the issue and is a contradiction to the existing a...
Other Medicine News:Health News:Booster dose not required for Hepatitis B Vaccination 2Health News:The Polymicrobial Nature Of Diabetic Foot Infections 2Health News:Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief 2
(Date:8/27/2008)...ght in Parts of Bucks, Delaware, Montgomery,Phila...swire-USNewswire/ -- After encouraging,results fol...epartment of,Environmental Protection will continu...gainst the mosquito-borne West Nile virus., Targe... 8 p.m. and,midnight in portions of Bucks, Delawar...
(Date:8/27/2008)...CADE, melphalan and prednisone arm demonstrated a,...cent complete response -, CAMBRIDGE, Mass., Aug. ... Company today announced the publication of result...A(1) trial in this week,s edition of the,New Engla...ficant survival,benefit and a 30 percent complete ...
(Date:8/27/2008)...st 27 /-, - Oralair(R) Gra...harmacodynamic Study Conducted in an Allergen Chal...ghly positive results of a new study,conducted in ...n Oralair(R) Grasses included 86 adult patients ex...atment durations: 1 week, 1 month,2 and 4 months ...
(Date:8/27/2008)...a, from BLISS-52 trial, expected by mid-2009 - - ... by fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewsw...daq: HGSI ) today announced it has completed enro...of two pivotal Phase 3,randomized clinical trials ...tive systemic lupus erythematosus (SLE). Belimumab...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 1Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 2Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 3Smokers Cost Medicaid System Nearly 2410 Billion 7170 1Smokers Cost Medicaid System Nearly 2410 Billion 7170 2Smokers Cost Medicaid System Nearly 2410 Billion 7170 3Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 1Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 2Meniscal damage and the development of persistent knee pain 7168 1Meniscal damage and the development of persistent knee pain 7168 2Meniscal damage and the development of persistent knee pain 7168 3
...ults Indicate Bioequivalent Pharmacokinetics With ...X-514, SAN DIEGO, April 25, 2007 /PRNewswire-First...rmaceutical research and,development company focus...es for the treatment of cancer and infectious dise...nical pharmacokinetic,testing of ANX-514 (docetaxe...
...SEL, Switzerland, April 25, 2007 - Basilea Pharmac...udy results showing that,patients with severe chro... alitretinoin. In two previous randomized clinical... treating severe,chronic hand eczema in patients r...l demonstrated that patients responsive to initial...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box.
Silicone Capsule Polisher, 27 g. Silicon tip to provide squeegee effect. Overall length 22 mm. 5/box.
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box.
Medicine Products: